[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Clinique de Retine de l'est\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100602878","phase-3-high-dose-hd-aflibercept-switch-in-neovascular-age-related-macular-degeneration-namd-to-load-or-maintain-heirloom-100602878",false,"NCT07129239","High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)","HEIRLOOM","Inclusion Criteria:\n\n* Patients over the age of 18\n* Patients with neovascular AMD\n* Patients who have received aflibercept 2mg for a minimum of 3 loading injections plus 2 maintenance injections.\n* Can include 1 or 2 eyes per patient if one or both meet study criteria.\n\nExclusion Criteria:\n\n* Patients with other maculopathy, including but not limited to:\n* Polypoidal choroidal vasculopathy\n* Macular dystrophies (ie. Pattern dystrophy, central areolar etc.)\n* Toxic\u002Fdrug induced maculopathies\n* Disciform scar\n* Subfoveal atrophy\n* Previous Photodynamic Therapy (PDT) or focal laser\n* Is currently enrolled in another clinical study or observational study\n* Active use of a different agent in the fellow eye, to avoid cross-over effects of anti Vascular Endothelial Growth Factor (VEGF) administration to the fellow eye\n* If the patient is pregnant","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg).\n\nEYLEA® HD is approved by Health Canada has been tested in large clinical trials involving thousands of patients around the world and has been shown effective in the treatment of wAMD. The treatment regimen used in these trials involved 3 initial monthly injections of EYLEA® HD followed by an extension of the treatment interval on the 4th visit. This was necessary since all patients in this study did not previously have treatment injections for wAMD.\n\nCurrently there is not enough information on the best treatment regimen to use for patients that are switched to EYLEA® HD from EYLEA®.\n\nHealth Canada currently recommends that EYLEA® HD is administered every month for the first 3 doses, followed by a treatment every 8 to 16 weeks.\n\nA total of 180 patients \\>18 years of age will participate in this study, which will be conducted at the Clinique de Retine de l'Est in Montreal, Quebec, Canada.",[26],"Wet Age-related Macular Degeneration (wAMD)","NOT_YET_RECRUITING","2025-08-11",{"date":30,"type":31},"2025-08-19","ACTUAL",{"date":33,"type":20},"2025-08-20",{"date":35,"type":20},"2027-02",{"name":37,"class":38},"Clinique de Retine de l'est","OTHER",""]